Without key, cross-silo information, employers that implement medical cost controls via pharmacy plan design for employees run the risk of discouraging treatment essential to employees’ health-related productivity and quality of life. This IBI study, relying on a master database furnished by Ingenix, demonstrates the unanticipated consequences in increased short-term disability and lost productivity for rheumatoid arthritis (RA) that can occur when employers increase out-of-pocket expenses for necessary medications. If new “value-based benefit designs” are truly going to add demonstrated value, they must draw treatment, cost and impact links across traditional benefits lines through an integrated database.

Related Posts
    Current or Archive

    see all topics

    see all topics
    Keyword Search
      National Heart Month: Promoting Healthy Behaviors at Work to Reduce Heart Disease Risk
      Feb 27, 2023
      Considering Equity and Employee Needs in Benefit Design Strategy
      Jan 19, 2023
      Solving the Challenges of a Remote or Hybrid Workplace
      Dec 6, 2022

      IBI Membership


      Get access to the latest tools and research on health and productivity.

      IBI Tools


      Use our resources and proprietary tools to turn data into action.